ArticleOncotarget2018
Distinct lung cancer subtypes associate to distinct drivers of tumor progression.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Regulatory Roles of Long Non-Coding RNAs in Methotrexate Pharmacology: Mechanistic and Translational Insights.Pharmaceutical research · 2026Review
- SNCA Overexpression Induces Apoptosis in Non-Small Cell Lung Cancer via Caspase-Dependent Signaling Pathways.BioMed research international · 2026Article
- Downregulation of PRPS2 inhibits tumor growth of non-small cell lung cancer by suppressing PI3K/AKT signaling.Frontiers in medicine · 2026Article
- Tumor suppressors in Sox2-mediated lung cancers promote distinct cell-intrinsic and immunologic remodeling.JCI insight · 2025Article
- A gene set enrichment analysis for cancer hallmarks.Journal of pharmaceutical analysis · 2025Article
- A clustering approach to integrative analyses of multiomic cancer data.Journal of applied statistics · 2025Article
- Demographic bias in misdiagnosis by computational pathology models.Nature medicine · 2024Article
- Multiomics-Based Feature Extraction and Selection for the Prediction of Lung Cancer Survival.International journal of molecular sciences · 2024Article
- Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity.Scientific reports · 2024Article
- ML-GAP: machine learning-enhanced genomic analysis pipeline using autoencoders and data augmentation.Frontiers in genetics · 2024Article
- Article
- The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.Nature cancer · 2023Article
- Phylogenetic conservation of Trop-2 across species-rodent and primate genomics model anti-Trop-2 therapy for pre-clinical benchmarks.Frontiers in genetics · 2023Article
- A non-mutatedFrontiers in oncology · 2023Article
- Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma.Clinical epigenetics · 2022Article
- Identification of condition-specific regulatory mechanisms in normal and cancerous human lung tissue.BMC genomics · 2022Article
- DNA Methylation-Mediated Low Expression of CFTR Stimulates the Progression of Lung Adenocarcinoma.Biochemical genetics · 2022Article
- Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.Scientific reports · 2021Article
- Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.Neoplasia (New York, N.Y.) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main non-small-cell lung cancer (NSCLC) histopathological subtypes are lung adenocarcinomas (LUAD) and lung squamous cell carcinomas (LUSC). To identify candidate progression determinants of NSCLC subtypes, we explored the transcriptomic signatures of LUAD versus LUSC. We then investigated the prognostic impact of the identified tumor-associated determinants. This was done utilizing DNA microarray data from 2,437 NSCLC patients. An independent analysis of a case series of 994 NSCLC was conducted by next-generation sequencing, together with gene expression profiling from GEO (https://www.ncbi.nlm.nih.gov/geo/). This work led us to identify 69 distinct tumor prognostic determinants, which impact on LUAD or LUSC clinical outcome. These included key drivers of tumor growth and cell cycle, transcription factors and metabolic determinants. Such disease determinants appeared vastly different in LUAD versus LUSC, and often had opposite impact on clinical outcome. These findings indicate that distinct tumor progression pathways are at work in the two NSCLC subtypes. Notably, most prognostic determinants would go inappropriately assessed or even undetected when globally investigating unselected NSCLC. Hence, differential consideration for NSCLC subtypes should be taken into account in current clinical evaluation procedures for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.